Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a common arrhythmia.
• Persistent AF requires effective rhythm control strategies.
• Amiodarone is an antiarrhythmic drug used to treat AF.

Purpose of the Study:

• To compare the effectiveness of 3 months versus 18 months of amiodarone treatment after successful AF conversion.
• To evaluate amiodarone's role in maintaining sinus rhythm after the first episode of persistent AF.

Main Methods:

• 51 patients with first-episode persistent AF received initial amiodarone therapy.
• Electrical cardioversion (ECV) was used if AF persisted.
• Patients were randomized to 3 months of amiodarone (Group I) or placebo (Group II) for 15 months post-conversion.
• A control group of 9 untreated patients undergoing ECV was included.
• Bayesian modeling was used for treatment effectiveness evaluation.

Main Results:

• After 18 months, 81.5% of Group I patients maintained sinus rhythm compared to 54.2% in Group II and 11.1% in the control group.
• Sinus rhythm was maintained in all Group I patients whose rhythm was restored during amiodarone administration.
• Adverse effects were minimal in Group I (11.1%).

Conclusions:

• A 3-month amiodarone regimen after AF reversion is a viable strategy for rhythm control.
• This duration provides a reasonable balance between efficacy and treatment duration for managing persistent AF.